Drug Profile
WBP 216
Alternative Names: Long-acting anti-IL6 antibody - AstraZeneca; MEDI-5117; WBP216Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer MedImmune; WuXi AppTec
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation; Rheumatoid arthritis
Most Recent Events
- 20 Jan 2021 Discontinued - Phase-I for Rheumatoid arthritis in China (IV), prior to January 2021 (AstraZeneca pipeline, January 2021)
- 20 Jan 2021 Discontinued - Preclinical for Autoimmune disorders in China (IV), prior to January 2021 (AstraZeneca pipeline, January 2021)
- 20 Jan 2021 Discontinued - Preclinical for Inflammation in China (IV), prior to January 2021 (AstraZeneca pipeline, January 2021)